Patient Preferences in the Management of Wet Age-Related Macular Degeneration: A Conjoint Analysis

Skelly, A; Taylor, Nigel; Fasser, Christina; Malkowski, Jean-Pierre; Goswamy, Pushpendra; Downey, Louise

doi:10.1007/s12325-022-02248-5

Cited by 7 publications

(3 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, our results are limited to ranibizumab and a T&E regimen with two-week increment intervals, as T&E is considered the most used treatment regimen in clinical practice [ 5 , 6 , 7 ]. Future studies are required to evaluate other anti-VEGF agents that allow longer intervals of extension, such as aflibercept [ 30 ], brolucizumab, or faricimab as it is necessary to consider anatomical and biochemical data as well as functional data and patients’ perceptions to obtain optimal results in management of nAMD [ 7 , 10 , 27 , 28 , 42 ].…”

Section: Discussionmentioning

confidence: 99%

Relationships between Patient-Reported Outcome Measures and Clinical Measures in Naïve Neovascular Age-Related Macular Degeneration Patients Treated with Intravitreal Ranibizumab

Almuiña-Varela,

García-Quintanilla,

Rodríguez-Cid

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

Our objective was to evaluate changes in patient-reported outcome measures using the NEI-VFQ 25 questionnaire during a treat and extend regimen in naive neovascular Age-Related Macular Degeneration patients, and its correlation with anatomical and functional data. We conducted a prospective observational study. Patients underwent a treat and extend regimen with intravitreal ranibizumab for neovascular Age-Related Macular Degeneration. Initial response was evaluated at 4th month, and subsequently in every follow-up visit. If a clinical response was achieved, the injection interval was extended in two-week increments, up to a maximum of 12 weeks. Quality of life was assessed using the NEI-VFQ 25 questionnaire at baseline, 4th months, and 12th months. Patients were categorized as good or poor responders based on Best corrected visual acuity, central foveal thickness, intraretinal fluid, or subretinal fluid. Treatment with ranibizumab led to a significant improvement in quality of life, with a mean increase in NEI-VFQ 25 score of 4.27 points in the 12th month. No significant differences in improvement were observed between good and poor responders. Quality of life scores in neovascular Age-Related Macular Degeneration patients improved with intravitreal treatment regardless of the clinical response. The early response following the loading phase could indicate better quality of life after one year of treatment, with Best corrected visual acuity being the clinical parameter with the greatest influence on quality of life.

show abstract

Section: Discussionmentioning

confidence: 99%

Relationships between Patient-Reported Outcome Measures and Clinical Measures in Naïve Neovascular Age-Related Macular Degeneration Patients Treated with Intravitreal Ranibizumab

Almuiña-Varela,

García-Quintanilla,

Rodríguez-Cid

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

show abstract

“…Assessing anxiety can identify that there is also a fear of the injection itself during treatment and that the efficacy of the treatment is the most important outcome for patients, as previous studies pointed out [23,24]. Patients, therefore, declared their willingness to take certain risks or accept discomfort and inconveniences [25]. Although the possibility of aversions and unconscious preferences cannot be ruled out, the acceptance of intravitreal therapy is generally very high [26], as evidenced by the strongly positive treatment satisfaction outcomes observed in our study.…”

Section: Discussionmentioning

confidence: 99%

The Psychological, Social and Behavioral Impact of Intravitreal Anti-VEGF Therapy: An Analysis from the ALBATROS Data

Wolfram,

Pfeiffer,

Hudde

et al. 2023

JCM

View full text Add to dashboard Cite

Background: Retinal diseases such as neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), or branch/central retinal vein occlusion (B/CRVO) have significant implications for patients’ social and psychological well-being. The ALBATROS study aimed to assess the care situation of patients who received anti-VEGF (vascular endothelial growth factor) treatment. To gain a comprehensive understanding of patients’ backgrounds and attitudes, we developed an exploratory, structured questionnaire, the Basic Care and Patient Satisfaction Questionnaire (BPZ-9). Methods: The data collection took place at the beginning and after twelve months of anti-VEGF therapy. The BPZ-9 questionnaire comprises nine questions to evaluate patients’ psychological and social situation and satisfaction with treatment. Results: Data were collected from 1478 nAMD (mean 78 years), 445 DME (67 years), 233 BRVO (70 years), and 144 CRVO (71 years) patients at 102 study centers throughout Germany. One in four patients had difficulties walking, and one in five needed an accompanying person for treatment. Anxiety about losing vision was present in three out of four patients at the beginning, and it slightly decreased to two out of three patients over the 12-month treatment period. The distress of having a retinal disease was generally higher than the distress related to the treatment. Most patients reported high treatment satisfaction (73%) and felt well-informed (81%). Conclusions: There is a relevant social and psychological impact related to anti-VEGF treatment. The patients’ perception, attitudes, and commitment need further investigation.

show abstract

“…However, existing treatment options (bevacizumab, ranibizumab, and aflibercept) have a considerable rate of incomplete therapeutic responses related to persistent retinal fluid, a high treatment demand, and an unacceptable treatment burden. This incomplete treatment response leads to long-term preventable vision loss as well as the progression of the underlying vascular pathology in AMD [2][3][4][5][6][7] and DME [8][9][10][11]. To some extent, optimizing the treatment strategies has improved the outcomes in nAMD [12][13][14], but not in DME [15].…”

Section: Introductionmentioning

confidence: 99%

Functional Outcomes of Brolucizumab-Induced Intraocular Inflammation Involving the Posterior Segment—A Meta-Analysis and Systematic Review

Garweg

Keiper

Pfister

et al. 2023

JCM

View full text Add to dashboard Cite

Early poor outcomes of intraocular inflammation (IOI) after intravitreal brolucizumab (IVB) have negatively affected the use of brolucizumab in clinical routine. We wished to identify factors related to the treatment details of IOI involving the posterior segment resulting from IVB for neovascular AMD (nAMD), if these were reported in detail. Articles were retrieved from PubMed, Scopus, ClinicalTrials, and CENTRAL using the following search terms: <Brolucizumab> AND <AMD> AND <intraocular inflammation>. The risk of bias was rated using the JBI Critical Appraisal Tool. We included 31 reports (41 patients and 46 eyes). Patients were 75.9 ± 8.5 years, and 58.5% were female. IOI occurred 41.7 ± 37.5 (median 37.0) days after treatment initiation with 2.0 ± 1.3 (1–6) IVB injections. A mean change in visual acuity of −14.6 ± 21.0 (median −6.5) letters was reported. The mean time from first IOI signs to the initiation of any anti-inflammatory treatment was 3.3 ± 6.2 days, with 63% of the patients receiving systemic corticosteroids as standard treatment. Finally, a period effect was observed, with a change in visual acuity of −25.3 ± 27.1 and −2.6 ± 7.3 letters in the chronologically first and last third, respectively, of treated eyes (effect size: r = 0.71; p = 0.006). Functional outcomes markedly improved with increasing experience in managing IOI.

show abstract

Patient Preferences in the Management of Wet Age-Related Macular Degeneration: A Conjoint Analysis

Cited by 7 publications

References 43 publications

Relationships between Patient-Reported Outcome Measures and Clinical Measures in Naïve Neovascular Age-Related Macular Degeneration Patients Treated with Intravitreal Ranibizumab

Relationships between Patient-Reported Outcome Measures and Clinical Measures in Naïve Neovascular Age-Related Macular Degeneration Patients Treated with Intravitreal Ranibizumab

The Psychological, Social and Behavioral Impact of Intravitreal Anti-VEGF Therapy: An Analysis from the ALBATROS Data

Functional Outcomes of Brolucizumab-Induced Intraocular Inflammation Involving the Posterior Segment—A Meta-Analysis and Systematic Review

Contact Info

Product

Resources

About